Pharmsynthez Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 94

Employees

  • Stock Symbol
  • LIFE

Stock Symbol

  • Investments
  • 4

Pharmsynthez General Information

Description

Pharmsynthez PJSC is a pharmaceutical company developing new medications, technologies of drugs for organ-specific delivery and innovative methods of manufacture for pharmaceutical ingredients. The company is engaged in the research and development, production and sales of officinal medicines (original OM) and active pharmaceutical ingredients (API).

Contact Information

Website
www.pharmsynthez.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Kuzmolovsky, Street Zavodskaya, building 3, building 134
  • Vsevolozhsk
  • Saint Petersburg, 188663
  • Russia
+7 8
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Laboratory Services (Healthcare)
Stock Exchange
MISX
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • Kuzmolovsky, Street Zavodskaya, building 3, building 134
  • Vsevolozhsk
  • Saint Petersburg, 188663
  • Russia
+7 8

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharmsynthez Financials Summary

As of 30-Jun-2023, Pharmsynthez has a trailing 12-month revenue of $4.95M.

In Thousands,
USD 		TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
Revenue 4,954 5,535 5,948 5,145
EBITDA (3,433) (2,041) (9,065) (6,306)
Net Income (4,371) (3,025) (9,465) (7,265)
Total Assets 19,740 17,959 19,115 27,581
Total Debt 8,759 10,005 9,497 8,380
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pharmsynthez Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharmsynthez‘s full profile, request access.

Request a free trial

Pharmsynthez Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Pharmsynthez Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3692370-A2 Articles and methods directed to personalized therapy of cancer Pending 04-Oct-2017
US-20200400676-A1 Articles and methods directed to personalized therapy of cancer Active 04-Oct-2017
JP-2024133625-A Articles and methods directed to personalized therapy of cancer Pending 04-Oct-2017
US-20100144780-A1 Salts of n-acridonacetic acid such as n-(1-deoxy-d-glucitol-1-yl)-n-ethyl ammonium 9-oxoacridine-10-ylacetate, having immunomodulating, antiparasitic, antisclerotic, antiviral, antibacterial, antifungal, antiphlogistic, antitumor, radioprotective and stressprotective activities Active 21-Nov-2005
US-7846939-B2 Salts of n-acridonacetic acid such as n-(1-deoxy-d-glucitol-1-yl)-n-ethyl ammonium 9-oxoacridine-10-ylacetate, having immunomodulating, antiparasitic, antisclerotic, antiviral, antibacterial, antifungal, antiphlogistic, antitumor, radioprotective and stressprotective activities Inactive 21-Nov-2005 C07D219/06
To view Pharmsynthez’s complete patent history, request access »

Pharmsynthez Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharmsynthez Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharmsynthez‘s full profile, request access.

Request a free trial

Pharmsynthez Investments & Acquisitions (4)

Pharmsynthez’s most recent deal was a Merger/Acquisition with Vaktsiny. The deal was made on 19-Nov-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vaktsiny 19-Nov-2020 Merger/Acquisition Pharmaceuticals
LIFEBio Laboratories 09-Jul-2012 Merger/Acquisition Distributors (Healthcare)
SynBio 30-Nov-2011 Early Stage VC Drug Discovery
Kevelt 17-Jan-2011 Merger/Acquisition Pharmaceuticals
To view Pharmsynthez’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Pharmsynthez Exits (1)

Pharmsynthez’s most recent exit was on 30-Nov-2011 from SynBio. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
SynBio 30-Nov-2011 Completed
  • 6 buyers
To view Pharmsynthez’s complete exits history, request access »

Pharmsynthez Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Kevelt Tallinn, Estonia 1992

Pharmsynthez FAQs

  • When was Pharmsynthez founded?

    Pharmsynthez was founded in 1996.

  • Where is Pharmsynthez headquartered?

    Pharmsynthez is headquartered in Saint Petersburg, Russia.

  • What is the size of Pharmsynthez?

    Pharmsynthez has 94 total employees.

  • What industry is Pharmsynthez in?

    Pharmsynthez’s primary industry is Pharmaceuticals.

  • Is Pharmsynthez a private or public company?

    Pharmsynthez is a Public company.

  • What is Pharmsynthez’s stock symbol?

    The ticker symbol for Pharmsynthez is LIFE.

  • What is Pharmsynthez’s current revenue?

    The trailing twelve month revenue for Pharmsynthez is $4.95M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »